Protosappanin B activates the Wnt pathway to protect against glucocorticoid-induced osteoblast inhibition and enhance bone formation
Authors:
- 20 February 2025
- journal article
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 410, 111436
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 43 references indexed in Scilit:
- Cost-effectiveness intervention thresholds for romosozumab and teriparatide in the treatment of osteoporosis in the UKOsteoporosis International, 2024
- 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced OsteoporosisArthritis & Rheumatology, 2023
- Glucocorticoid-induced osteoporosis: an overview with focus on its prevention and managementHormones, 2023
- Wnt signaling: Essential roles in osteoblast differentiation, bone metabolism and therapeutic implications for bone and skeletal disordersGenes & Diseases, 2023
- Salidroside alleviates dexamethasone‐induced inhibition of bone formation via transforming growth factor‐beta/Smad2/3 signaling pathwayPhytotherapy Research, 2022
- Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disordersOsteoporosis International, 2022
- Glucocorticoid-Induced Osteoporosis: New Insights into the Pathophysiology and TreatmentsCurrent Osteoporosis Reports, 2019
- Protosappanin B protects PC12 cells against oxygen–glucose deprivation-induced neuronal death by maintaining mitochondrial homeostasis via induction of ubiquitin-dependent p53 protein degradationEuropean Journal of Pharmacology, 2015
- Wnt6, Wnt10a and Wnt10b inhibit adipogenesis and stimulate osteoblastogenesis through a β-catenin-dependent mechanismBone, 2012
- Wnt/β-Catenin Signaling: Components, Mechanisms, and DiseasesDevelopmental Cell, 2009